SUNNYVALE, CA--(Marketwire - September 21, 2009) - Arrayit Corporation (OTCBB: ARYC), a
proprietary life sciences and nanotechnology technology leader, announces
that on September 11th, 2009 Arrayit delivered its proprietary
nanotechnology platform to Sandia National Laboratories in Albuquerque, New
Mexico. Sandia Labs, managed by the Lockheed Martin Corporation, works with
the Transportation Security Administration (TSA) and the Department of
Homeland Security to enhance national security.
Sandia will utilize Arrayit's proprietary nanotechnology manufacturing
platform, which empowers researchers to create microarrays, biosensors and
"chemical noses" that detect the biological and chemical agents used in
lethal terrorist attacks. Arrayit's patented delivery system deposits
nanoliter quantities of analytical reagents onto proprietary substrates to
create the sophisticated detection devices.
"We are pleased to receive this contract from the prestigious Sandia Labs,"
states Rene Schena, CEO and co-founder of Arrayit Corp. "We look forward to
leveraging our unique and patented nanotechnology capabilities to enhance
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and
empowers the genetic, research, pharmaceutical, and diagnostic communities
through the discovery, development and manufacture of proprietary life
science technologies and consumables for disease prevention, treatment and
cure. It now offers over 650 products to a customer base of more than 2,500
laboratories worldwide, including most every major university,
pharmaceutical and biotech company, major agricultural and chemical
company, government agency, national research foundation and many private
sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this
release that would constitute forward-looking statements may involve
certain risks and uncertainties. All forward-looking statements made in
this release are based on currently available information and the Company
assumes no responsibility to update any such forward-looking statement. The
following factors, among others, may cause actual results to differ
materially from the results suggested in the forward-looking statements.
The factors include, but are not limited to, risks that may result from
changes in the Company's business operations; our ability to keep pace with
technological advances; significant competition in the biomedical business;
our relationships with key suppliers and customers; quality and consumer
acceptance of newly introduced products; market volatility;
non-availability of product; excess inventory; price and product
competition; new product introductions, the outcome of our legal disputes;
the possibility that the review of our prior filings by the SEC may result
in changes to our financial statements; and the possibility that
stockholders or regulatory authorities may initiate proceedings against
Arrayit and/or our officers and directors as a result of any restatements.
Risk factors associated with our business, including some of the facts set
forth herein, are detailed in the Company's Form 10-K for the fiscal year
ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended
March 31, 2008 and Form 10-Q for the fiscal third quarter ended September